AE-941 (AEterna)

Current Opinion in Investigational Drugs

Volumn 5, Issue 6, 2004, Pages 668-677

  Dredge, Keith ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG; SHARK CARTILAGE EXTRACT AE 941; TISSUE EXTRACT;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; REVIEW; STATISTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; LUNG NEOPLASMS; TISSUE EXTRACTS;

EID: 4043116451     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. 222703 Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Sadove AM, Kuettner KE SURG FORUM 1977 28 1
2. 224400 AEterna Laboratories Inc third quarter results - promising preclinical results for Neovastat (AE-941) and filing of an IND application. AEterna Laboratories Inc PRESS RELEASE 1996 November 05
3. 230068 AEterna begins phase I/II studies for cancer in the United States. Les Laboratoires AEterna Inc PRESS RELEASE 1997 January 16
4. 235387 AEterna Laboratories announces a strategic alliance in ophthalmology. Les Laboratoires AEterna Inc PRESS RELEASE 1997 February 25
5. 243026 AEterna Laboratories Inc presented preclinical results on lung and breast cancer at the conference of the American Association for Cancer Research. Les Laboratoires AEterna Inc PRESS RELEASE 1997 April 18
6. 251346 Annual Report 1996 - Les Laboratoires. Les Laboratories AEterna Inc ANNUAL REPORT 1996 December
7. 255534 Angiostatic and antitumoral activity of AE-941 (Neovastat), a molecular fraction derived from shark cartilage. Dupont E, Alaoui Jamali M, Wang T, Doillon C, Ross N, Thibodeau A, Alpert L, Savard P, Falardeau P PROC ANNU MEET AM ASSOC CANCER RES 1997 38 Abs 227
8. 261878 First encouraging results for osteoarthritis treatment - Arthrovas. AEterna Laboratories Inc PRESS RELEASE 1997 September 08
9. 264680 AEterna: Positive combination of chemotherapy and Neovastat. AEterna Laboratories Inc PRESS RELEASE 1997 September 29
10. 264954 First patient enrolled in the study on AMD. AEterna Laboratories Inc PRESS RELEASE 1997 September 16
11. 275857 AEterna: First clinical results from the phase I/II on lung cancer. AEterna Laboratories Inc PRESS RELEASE 1998 January 30
12. 282610 Liquid shark cartilage extract shows encouraging results to cancer experts. AEterna Laboratories Inc PRESS RELEASE 1998 March 30
13. 317916 Angiogenesis: Therapeutic Applications, Bethesda, MD, USA. Williams J IDDB MEETING REPORT 1999 February 22-23
14. 319148 AEterna: Improvement in the PASI score of psoriasis patients treated with AE-941/Psovascar in phase I/II trial. AEterna Laboratories Inc PRESS RELEASE 1999 March 22
15. 337944 Phase I/II clinical trials of escalating dose of AE-941, an inhibitor of angiogenesis, in patients with refractory lung cancer. Latreille J, Laberge F, Riviere M, Falardeau P, Champagne P, Croteau D, Dupont E, Chum C PROC ANNU MEET AM ASSOC CANCER RES 1999 40 92 Abs 611
16. 337949 Effect of AE-941 (neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention and survival. Jamali MA, Riviere M, Falardeau P, Thibodeau A, Dimitriadou V, Dupont E CLIN INVEST MED 1998 21 Suppl S16
17. 339618 AEterna Laboratories presents new phase I/II data on its antiangiogenesis compound AE-941/Neovastat in lung cancer -retrospective analysis suggests that AE-941/Neovastat improves the survival of patients with locally recurrent or metastatic non-small-cell lung cancer when treated. AEterna Laboratories Inc PRESS RELEASE 1999 September 14
18. 353013 AEterna Laboratories Inc - National Cancer Institute to begin phase 3 trial of AE-941/Neovastat in lung cancer patients in the US and Canada. AEterna Laboratories Inc PRESS RELEASE 2000 January 20
19. 358517 AEterna confirms data on AE-941/Neovastat's mechanism of action at an angiogenesis symposium - AE-941/Neovastat blocks two main pathways in the angiogenic process. AEterna Laboratories Inc PRESS RELEASE 2000 March 06
20. 362515 Antiangiogenic agent AE-941 induces in vivo and in vitro inhibition of VEGF. Beliveau R, Sirois P, Tranqui L, Baffert F, Dimitriadou V, Pepin MC, Sirois MG, Poyet P, Falardeau P, Dupont E PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3617
21. 388236 Evaluating Anti-angiogenic Therapies - Third Annual IIR Conference, Conducting Successful Oncological Clinical Trials for Angiogenesis Inhibitors Workshop, London, UK. Williams J IDDB MEETING REPORT 2000 October 18-19
22. 389673 In vivo antitumoral activity of the multifunctional antiangiogenic agent Neovastat/AE-941 in experimental gliomas. Berger F, Jourdes P, Benabid AL NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 November 7-11 272
23. 408337 AEterna reports on its pivotal phase II trial on multiple myeloma -patient recruiting is under way in 35 investigative centres in North America and Europe. AEterna Laboratories Inc PRESS RELEASE 2001 May 08
24. 408520 NCI-sponsored trial tests shark cartilage extract in patients with non-small cell lung cancer. National Cancer Institute PRESS RELEASE 2001 May 09
25. 409236 AEterna's patient recruitment has reached the halfway mark in its phase III trial in renal cell carcinoma. AEterna Laboratories Inc PRESS RELEASE 2001 May 15
26. 409989 Neovastat (AE-941) induces the expression of angiostatin in experimental glioma. Berger F, Jourdes P, Pernod G, Benabid A-L PROC AM SOC CLIN ONCOL 2001 20 1 Abs 397
27. 410742 Phase I/II trials on the safety, tolerability and efficacy of AE-941 (Neovastat) in patients with solid tumors. Franqois B, Champagne P, Evans W, Jean L, Gerald B, Falardeau P, Hariton C, Dupont E PROC AM SOC CLIN ONCOL 2001 20 Abs 2861
28. 412510 AEterna discovers potent antiangiogenic activity in a class of molecules isolated from Neovastat - company files new patent application. AEterna Laboratories Inc PRESS RELEASE 2001 June 13
29. 413650 AEterna: Phase I/II study results in prostate cancer confirm Neovastat's safety profile and dose-related activity. AEterna Laboratories Inc PRESS RELEASE 2001 June 26
30. 433433 Neovastat (AE-941) in multiple myeloma. Jagannath S, Champagne P, Hariton C BLOOD 2001 98 11 Suppl 2 Abs 4990
31. 440243 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E SEMIN ONCOL 2001 28 6 620-625
32. 453109 Dose-survival relationships in phase 2 study of neovastat in refractory renal cell carcinoma patients. Batist G, Champagne P, Hariton C, Dupont E PROC AM SOC CLIN ONCOL 2002 21 1 Abs 1907
33. 455239 AEterna Laboratories Inc. INT BIOTECH CONV & EXHIB 2002 Suppl June 9-12
34. 456329 Multiple myeloma phase II clinical trial. AEterna Laboratories Inc COMPANY WORLD WIDE WEB SITE 2002 June 26
35. 456334 Drug development update: AE-941. AEterna Laboratories Inc COMPANY COMMUNICATION 2002 June 26
36. 458018 The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Weber MH, Orr FW INT J ONCOL 2002 20 2 299-303
37. 458021 The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V et al CLIN CANCER RES 2002 8 4 1242-1250
38. 476077 AEterna reports on its new product pipeline and clinical development strategy following Zentaris acquisition. AEterna Laboratories Inc PRESS RELEASE 2003 January 13
39. 477023 Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E ANN ONCOL 2002 13 8 1259-1263
40. 476670 Drug development pipeline: Neovastat, D-22213, PDGF receptor kinase inhibitors, GHRP, D-63153, perifosine, lobaplatin, cetrorelix, teverelix, EP-1572. Zentaris AG COMPANY COMMUNICATION 2003 January 20
41. 477026 The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R MOL CANCER THER 2002 1 10 795-802
42. 477042 Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E J AM ACAD DERMATOL 2002 47 4 535-541
43. 477046 Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Dupont E, Falardeau P, Mousa S, Dimitriadou V, Pepin MC, Wang T, Alaoui J CLIN EXP METASTASIS 2002 19 2 145-153
44. 484094 Modulation of plasminogen activator activities by Neovastat, an antiangiogenic drug in phase III clinical trials. Gingras D, Nyalendo C, Trudel S, Labelle D, Beliveau R PROC ANNU MEET AM ASSOC CANCER RES 2003 44 Abs 56
45. 486796 AEterna discloses new scientific data on Neovastat. AEterna Laboratories Inc PRESS RELEASE 2003 April 23
46. 487930 AEterna annual report 2002 - expanding our vision. AEterna Laboratories Inc ANNUAL REPORT 2003 March 30
47. 487978 Annual information form 2002. AEterna Laboratories Inc COMPANY PUBLICATION 2002 May 10
48. 491181 AEterna Laboratories holds annual meeting - the company presents its new position in the international biopharmaceutical sector. AEterna Laboratories Inc PRESS RELEASE 2003 May 29
49. 491457 A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report. Lu C, Komaki R, Herbst RS, Evans WK, Smith TL, Moore CA, Kolbye SL, Choi NC, Choy H, Bleyer C PROC AM SOC CLIN ONCOL 2003 22 Abs 2665
50. 491907 Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Escudier B, Venner P, Buckowski R, Szczylik C, Oudard S, Champagne P, Hariton C, Dupont E PROC AM SOC CLIN ONCOL 2003 22 Abs 844
51. 493831 Drug status validation: Marimastat. British Biotech plc COMPANY COMMUNICATION 2003 June 13
52. 493833 Drug Development Pipeline - Bayer. Bayer AG COMPANY COMMUNICATION 2003 June 17
53. 500253 AEterna Laboratories reports second quarter results. AEterna Laboratories Inc PRESS RELEASE 2003 August 06
54. 500279 AEterna annual information form 2003. AEterna Laboratories Inc COMPANY PUBLICATION 2003 May 09
55. 506209 AEterna laboratories reports phase III trial results in renal cell carcinoma with Neovastat. AEterna Laboratories Inc PRESS RELEASE 2003 September 24
56. 506431 Drug development pipeline: AE-941. AEterna Laboratories Inc COMPANY COMMUNICATION 2003 September 25
57. 510661 Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E CLIN LUNG CANCER 2003 4 4 231-236
58. 510662 Modulation of the contact hypersensitivity response by AE-941 (Neovastat), a novel antiangiogenic agent. Dupont E, Wang B, Mamelak AJ, Howell BG, Shivji G, Zhuang L, Dimitriadou V, Falardeau P, Sauder DN J CUT MED SURG 2003 7 3 208-216
59. 510664 Neovastat - a novel antiangiogenic drug for cancer therapy. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R ANTICANCER DRUGS 2003 14 2 91-96
60. 513447 Presentation at CIBC World Markets Healthcare Conference. AEterna Laboratories Inc COMPANY PRESENTATION 2003 November 12
61. 517379 AEterna updates Neovastat's clinical development plan. AEterna Laboratories Inc PRESS RELEASE 2003 December 17
62. 525274 The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity. Gingras D, Labelle D, Nyalendo C, Boivin D, Demeule M, Barthomeuf C, Beliveau R INVEST NEW DRUGS 2004 22 1 17-26
63. 525275 Evaluating antiangiogenesis agents in the clinic: The Eastern Cooperative Oncology Group portfolio of clinical trials. Sparano JA, Gray R, Giantonio B, O'Dwyer P, Comis RL CLIN CANCER RES 2004 10 4 1206-1211
64. 527773 SELDI-TOF proteomic patterns in neuro-oncology: Molecular fingerprinting, biomarker applications and pharmaco-proteomic analysis in antiangiogenic therapy. Bouamrami A, Cubizole M, Gay E, Ratel D, Plattet N, Dupre I, Bernabid AL, Berger F PROC ANNU MEET AM ASSOC CANCER RES 2003 44 Abs 3031
65. 527775 Comparison of the 'transcriptomic signatures' of three antiangiogenic agents Neovastat, endostatin and angiostatin. Ratel D, Simard B, Dupre I, Atifi M, Puissant BR, Mantel F, Benabid AL, Berger F PROC ANNU MEET AM ASSOC CANCER RES 2003 44 Abs 1171
66. 527780 Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R ANTICANCER RES 2001 21 1A 145-155
67. 528810 Induction of tissue-type plasminogen activator gene transcription by Neovastat, a multifunctional anti-angiogenic drug. Nyalendo C, Gingras D, Beliveau R PROC ANNU MEET AM ASSOC CANCER RES 2004 45 Abs 82
68. 528811 Proteomic and transcriptomic functional analysis of Neovastat antiangiogenic effect: Importance of the t-PA/plasminogen system. Simard B, Bouamrani A, Pernod G, Berger F PROC ANNU MEET AM ASSOC CANCER RES 2004 45 Abs 83
69. 529949 Tumors of fishes, amphibians, and reptiles. Schlumberger HG, Lucke B CANCER RES 1948 8 657-754
70. 529989 Neoplasia and primitive vertebrate phylogeny: Echinoderms, prevertebrates, and fishes - A review. Wellings SR MONOGR NATL CANCER INST 1969 31 59
71. 529998 Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. Durie BG, Soehnlen B, Prudden JF J BIOL RESPONSE MODIF 2004 4 6 590-595
72. 530004 Shark cartilage contains inhibitors of tumor angiogenesis. Lee A, Langer R SCIENCE 1983 221 4616 1185-1187
73. 530006 Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer. Sridhar SS, Shephard FA LUNG CANCER 2004 42 S81-S91
74. 530025 Cancer in sharks, skates, rays, and other lower fishes. Harshbarger JC, Ostrander GK PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 4848
75. 536899 Shark and bovine cartilage therapies. Cassileth BR In: THE ALTERNATIVE MEDICINE HANDBOOK: THE COMPLETE REFERENCE GUIDE TO ALTERNATIVE AND COMPLEMENTARY THERAPIES Cassileth BR (Ed) WW Norton & Co, New York, NY, USA 1998 197-200